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Abstract: The article aimed to give a personal perspective on drug discovery and development. The author has 
worked both in Big Pharma as a scientist and manager and more recently also in start-up biotech companies. Drug 
companies have played a major important role in improving population health and will continue to do so. The hurdles 
and costs for drug development have continuously risen without a parallel enhancement of productivity. There is no 
single explanation for this and the article outlines success factors and hurdles for effective drug development. Aspects of 
the external and internal environments that influence Big Pharma productivity is outlined and discussed. 
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Introduction 
he international pharma industry faced a prod-
uctivity crisis during the last two decades 
which has been outlined in many publica-
tions[1]. The number of new drug (NCEs) approvals 
and introductions into the market has fallen, despite 
increasing R&D investments, clearly not a sustainable 
situation; fewer new drugs need to carry the costs of 
the failures. Furthermore, it has been estimated that 
some 300 000 employees have been laid-off as a con-
sequence of the productivity shortfalls[2], R&D units 
have been closed as part of a necessary consolidation 
and therapy areas have been abandoned. The big los-
ers in this drama are naturally the patients to whom 
new drugs can’t be offered. Despite advancements in 
healthcare, many diseases affecting large numbers of 
patients stand without effective treatment. During the 
last two years an increasing trend in new drugs ap-
provals can be observed. This is very positive and is 
mainly reflected in orphan indications and hence 
smaller patient segments, which historically were less 
in focus by Big Pharma industry, but now will benefit 
from this development. 
The author has been witnessing and been part of bl-
ock-buster successes as well as the downsizing of the 
industry, by working as both as scientist and manager 
in Big Pharma industry and the last years in small bi-
otech companies. The article aims to give reflections 
on his personal learning and perspectives on the in-
dustry’s developments. 
Role of Drug Companies in Improving and 
Maintaining Population Health 
Drug companies have delivered major contributions to 
patient and population health. This purpose is and 
will be of major importance, since only this industry 
possesses the complete set of capabilities, e.g., chemi-
stry, biomedical and pharmacological science, drug 
metabolism-, analytical-, formulation-, clinical trials- 
and regulatory competence to discover and develop 
novel drugs. Since major unmet medical needs re-
mains, future novel drug treatments need to contribute 
to population health. 
The purpose of the pharmaceutical companies, to 
contribute to patient health, is an important driver for 
scientists and staff working within the respective or-
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ganizations. This is contrasted to the often-given me-
dia picture of a profit-hungry industry making money 
out of sick people’s misfortunes. Part of this picture 
may stem from the perceived view of big pharma 
companies having focused to “blockbuster” drugs, 
whilst leaving out smaller segments of medical need. 
This strategy is now changing and smaller indications 
as well as orphan drugs will hopefully be pursued. The 
fact is that most scientists come to industry to make a 
difference to human health. Another fact is also that 
companies and their employees have been richly re-
warded for the contributions and rightly so, whilst 
there is great risks involved both for the scientist and 
manager, as well as for the investor. However, work-
ing with sick people as a customer comes with a great 
responsibility in terms of care for the individual pa-
tient and contribution to society. This responsibility 
goes far beyond profits, which are only a mere ex-
pression of success.     
Influencing Productivity Factors in the Phar-
maceutical Industry 
Fundamental Factors 
Complex Diseases:
Despite all rapidly developing science most human 
patho-physiologies are not easily described. With the 
exception of monogenic diseases, for which there is 
normally little cure, and infections, our understanding 
of exact disease progression is often limited and con-
stitutes a major hurdle for rational drug discovery and 
development. The interplay between our individual 
genomes and lifestyles is very complex. Despite these 
difficulties there are medical areas where novel drugs 
have contributed to better treatments, e.g., in autoim-
mune diseases, cancer, etc. However, to find a single 
target approach to the complex multifactorial diseases 
is normally very difficult because the compensatory 
mechanisms of the human body are forceful. On the 
other hand, in the event that most of the central bio-
logical processes are targeted, the side-effects are 
likely to come into play.    
 Patho-physiology and what we 
don’t know 
 
Preventable Diseases:
The westernized lifestyle, which came to societies in 
the wake of industrialization of farming and produc-
tion, is, in relation to health aspects, characterized by 
inactivity and overeating. As our bodies show a high 
level of phenotypic plasticity in response to the pre-
vailing environment, this has fundamental effects on 
disease patterns. Hence, for many of our major dis-
eases (e.g., cardiovascular, obesity, diabetes type 2, 
some cancer forms and osteoporosis) a major contri-
buting factor, in addition to genetic background, 
can be described as a mismatch between this new en-
vironment and the inadequate adaptation of our bodies 
to the challenge. 
 Our stone-age body in the wes-
ternized lifestyle 
Approaches to novel drug discovery in mismatched 
diseases must take lifestyle factors into account. Con-
tinued exposure of the human body with excess ener-
gy in form of carbohydrates and fat, inactivity and 
smoking will strongly limit the long-term success of 
drug treatment. The pharmaceutical industry needs to 
take a more holistic responsibility by engaging with 
medical professionals and political decision makers in 
the fight towards a healthier lifestyle. The problem is 
on the agenda through the United Nations 25×25 ap-
proach which is partly building on education and, if 
successful, it will have a major impact on non-comm-
unicable disease mortality[3].  
Internal Factors 
Ownership Structures and Influences:
The role of the ownership structure of the pharma-
ceutical industry has been debated and proposed as a 
major factor for the maintenance of corporate identity 
and resilience[
 ROI, endurance 
and passion 
4]. Drug discovery and development 
requires long-term and passionate view on investment, 
whilst this is a very lengthy and risky endeavor. Hence, 
it has been questioned if past and current ownership 
structures are the proper owners to maintain a long 
term view and to accept lower margins over long time. 
Clearly the contraction of the big Pharma industry 
has been a global event over the last two decades, with 
enormous loss of talent as a consequence of all major 
pharma companies has been subjected to endless 
mergers and acquisitions (M&A). In contrast, compa-
nies with different ownership structures, such as 
foundations, not-for-profit organizations and compa-
nies in private ownership, have been able to survive 
periods of diminishing returns and to pursue strategies 
with less external accountability. 
 
The Game R&D Plays:
Three decisions in the history of a novel project dic-
tate its fate. The first is the selection of the target, the 
second is the selection of the molecule and the third is 
 “One in twenty” 
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the selection of patients. From these decisions on-
wards the rest is documentation of the resulting effects 
and side effects.   
The pharmaceutical industry is different to other 
engineering industries in as much the ability to predict 
if a novel project will translate into a successful prod-
uct is very low. It has been estimated that 93% of can-
didate drugs fail to reach approval, let alone be suc-
cessful in the marketplace[5]. Despite the emergence of 
new technologies, increased development investments 
and longer development times productivity has fallen. 
The major contributing factors for failure are lack of 
efficacy and toxicity/clinical side effects[6]. The indus-
try has rapidly introduced novel strategies to rectify 
this situation, impressive advances in novel platforms, 
technologies and ways of working have been intro-
duced. Some examples include the following:  
(i) Advances in biomedical science platforms such 
as genetically engineered animals, stem cell approa-
ches, bioinformatics platforms and predictive science 
methodologies all aimed to improve and verify correct 
target selections. Recently, evidence has been pro-
vided that compounds co-developed with a biomarker 
have been associated with higher success rates. The 
concept of biomarker monitoring for efficacy and 
safety could bring significant contributions to overall 
success[7]. 
(ii) Novel platforms for drugs include, in addition 
to small molecules, biologicals (proteins, peptides, 
antibodies, and modern vaccines), RNA-interference 
molecules, cell therapy and gene therapy approaches. 
Particularly the more recent introduction of antibodies 
has been successful. 
(iii) Platforms for drug discovery include miniatu-
rization which expands the capacity of bioassays and 
chemical synthesis, profiling technologies such as 
transcriptomics, new imaging methods and ultra high 
throughput assays. 
 
Novel Project Strategies:
The technologies introduced above provided a means 
for rapid target selection and testing of large number 
of compounds. The fundamental strategic change of 
direction was based on the principle that a multitude 
of early development projects would mitigate for loss 
seen later in the development process. In this context, 
the principle coined by Sir James Black “the best way 
to create a new drug — is to start with an old one” was 
no longer in fashion. The new ways of working bro-
ught forward chemistry and novel molecules, however, 
at the expense of solid human target validation. Indus-
try paid a very high prize for this novel strategy in 
terms of development failures. Furthermore, it is also 
disappointing to note how little impact the introduc-
tion of novel technologies have had on improvement 
on success. In many companies the re-introduction of 
more integrated experimental models showing physi-
ological responses have been increasingly used in 
early drug evaluations. 
 Targets, new chemistry 
and big project portfolios 
Hindsight makes analysis easier and looking re-
trospect, the human target or treatment paradigm va-
lidation plays the most critical role in the success of a 
novel project in view of the author. The highest level 
of approach validation is based on existing drugs de-
monstrating clinical effects in the appropriate patient 
population. A relevant example is pharmacological 
treatment of peptic ulcer disease. The over many dec-
ades prevailing treatment paradigm, inhibition of acid 
secretion, clearly improve the 4-week healing rates of 
duodenal ulcers over placebo. Furthermore, progres-
sively more effective suppression of acid secretion by 
anti-cholinergic, H2-blockers and proton pump block-
ers further enhances healing rates. However, the fun-
damental cause of disease is not improved as evi-
dent by the high 2-year recurrent rates after cessation 
of treatment. It was not until the understanding of H. 
pylori as a causative agent of the disease was discov-
ered and its subsequent eradication by a combination 
of proton pump blockers and antibiotics that the dis-
ease could be ultimately cured. 
We learn from this that:  
(i) progression to effective treatment/cure is a 
long-term endeavor over many decades, 
(ii) several treatment modalities are normally in-
troduced to effectively treat a disease, 
(iii) fundamental understanding of disease patho- 
physiology is the most important factor for treatment 
success as well as human target validation. This has 
often been absent at the onset of many drug projects.  
 
Global Reach:
For the successful companies globalization is neces-
sary to provide for access to markets and new product 
opportunities. This means operation over many global 
corporate functions, cultures and co-workers. Func-
tions like R&D need to be managed globally, with the 
consequence that the same global standards, opera-
tional procedures, review and evaluations, budgets, etc 
 Consequences for scientists and entre-
preneurs 
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are instituted. In the growth transition from the smaller, 
fast moving unit to the globally governed one, deci-
sions move to higher organizational levels and take 
longer time, workflow is standardized and idea gener-
ation steered by corporate strategies. In a big Pharma 
company, some 100 different projects may run in dif-
ferent phases of development and with geographical 
spread. For an individual project leader to navigate the 
different strategy reviews and decision bodies, he 
needs to, in addition to ensure proper presentation of 
the subject matter, consider the in-house political 
landscape, lobby with stakeholders and advise on 
formal report progress.  
In order to generate economy of scale, Big Pharma 
companies often place central functions in large cen-
ters of excellence. The consequence for the individual 
scientist is that they often find their job role being 
narrowed down to do a single task and distanced to 
project work. The possibility to influence his or her 
own work becomes very limited. In this landscape it is 
clear that conditions for creative drug discovery are 
not optimal. 
 
Big Pharma People Management:
To align big pharma company objectives to the indi-
vidual level, these are cascaded in elaborated proc-
esses to staff. Fulfillment of these objectives forms 
the basis for evaluation of staff performance and sub-
sequently salaries and other compensation. The prob-
lem with “people management” in a big Pharma set-
ting is that it is not motivational and aligned to real 
drivers for scientists at different levels. The inherent 
risk of drug project failure and hence missing personal 
objectives drives co-workers to risk adverse behaviors 
and to become street-smart. Furthermore, due to the 
complexity of large organizations, skilled scientists 
soon find themselves devoting much of their time to 
meetings instead of research. Ironically in many big 
Pharma companies it is often more rewarding to take 
on an administrative career than to stay with science.  
 Counter to an inno-
vative climate? 
Scientists come to big Pharma industry because 
they want to make a difference to patients, to do good 
science in quality facilities and expect a good com-
pensation. For them to be engaged in this task they 
need to be given the possibility to strongly influence 
their own work, pursue ideas and to grow in their 
skills and take on more advanced duties. Success is 
to be associated with and being able to influence im-
portant drug projects to succeed.  
Small Biotech and Start-up Companies:
Part of the personnel being laid-off from big Pharma 
find themselves starting new careers as entrepreneurs 
in small biotech and start-up companies. The business 
ideas may build on an academic discovery, reposi-
tioning or reformulation of a known drug or research 
projects of little strategic importance to the Big Phar-
ma company. This is sometimes known as “open in-
novation”. These companies usually focus to one or 
few projects, lack the broad expertise, are flexible and 
fast in decision making, steered by results and the 
funding situation and show a high entrepreneurial 
commitment. The smaller company critically depends 
on external CRO competence and problem solving, 
such as deficits in compound quality often remaining 
too long in development. The customer to these com-
panies is often Big Pharma. 
 The solution 
to innovation? 
External Factors  
Socioeconomic Gains:
Many important drugs are becoming generic. This 
raises the hurdles for new drug development and the 
pressure on the industry to innovate with advantages 
for patients and for society becomes increasingly hig-
her. Furthermore, as health care providers are strug-
gling with budgets taking an ever-increasing part of 
taxpayer money, compensation for new drugs are crit-
ically reviewed. 
 What health care decision ma-
kers want 
Conclusion 
There is no simple recipe for successful drug discovery 
and one successful drug is no guarantee for a main-
tained pipeline. No pharmaceutical company is im-
mune towards patent expiries, negative price pressure 
and failing drugs. To summarize some of the learnings: 
The productivity, e.g., successful drug introductions, 
will continue not to be planable due to the biological 
complexity and lack of knowledge of patho-phy-
siology. Methods such as biomarkers, that can select 
patients that are more amenable for treatment, sho-
uld be prioritized.  
Drug development has to take the strong phenotyp-
ic influence of the westernized lifestyle into consider-
ation as disease patterns are rapidly changing. Big Ph-
arma should engage more forcefully with medical pro-
fessionals and politicians to massively inform the pop-
ulations as to the importance of a healthier lifestyle. 
Björn Wallmark 
 
 Advances in Precision Medicine, vol 1, issue 2, 2016 5 
The passion and resilience of Big Pharma owner-
ship together with the formation of a creative culture 
that fosters entrepeunurship and freedom to explore 
novel ideas is of fundamental importance. 
Cost for health care will rise and the pharma indus-
try has to get accustomed to operate to lower levels of 
return on investment. This will also improve Big 
Pharma reputation in the eyes of the society. 
Finally, drugs are discovered by scientists and their 
associated teams. Management need to better under-
stand their needs in terms of freedom to explore ideas 
and necessary funds, rather than managerial strive to 
control. 
Conflict of Interest and Funding 
No conflict of interest was reported by all authors 
Acknowledgements 
The author would like to thank Dr David Gustavsson 
for critically reviewing and giving valuable contribu-
tions to this paper. 
References 
1. Paul M S, Mytelka D S, Dunwiddie C T, et al. 2010, How 
to improve R&D productivity: the pharmaceutical indus- 
 
try’s grand challenge. Nature Reviews Drug Discovery, 
vol.9: 203–214. 
http://dx.doi.org/10.1038/nrd3078 
2. Herper M, 2011, A decade in drug industry layoffs, 
Forbes, viewed June 10, 2016,  
<http://www.forbes.com/sites/matthewherper/2011/04/13/
a-decade-in-drug-industry-layoffs/#4e9be1c25614>  
3. Kontis V, Mathers C D, Rehm J, et al. 2014, Contribution 
of six risk factors to achieving the 25×25 non-com-
municable disease mortality reduction target: a modeling 
study. The Lancet, vol.384(9941): 427–437. 
http://dx.doi.org/10.1016/S0140-6736(14)60616-4 
4. Nilsson T, 2010, When Sweden Sold the Nobel Prize 
Industry: The Story of Astra, Pharmacia and Kabi. 
Stockholm: SNS Förlag, Swedish.  
5. Kola I and Landis J, 2004, Can the pharmaceutical indus-
try reduce attrition rates? Nature Reviews Drug Discovery, 
vol.3: 711–715. 
http://dx.doi.org/10.1038/nrd1470 
6. Schuster D, Lagger C and Langer T, 2005, Why drugs fail 
— a study on side effects in new chemical entities. Cur-
rent Pharmaceutical Design, vol.11(27): 3545–3559. 
http://dx.doi.org/10.2174/138161205774414510 
7. Holland R L, 2016, What makes a good biomarker? Ad-
vances in Precision Medicine, vol.1(1): 4–11. 
http://dx.doi.org/10.18063/APM.2016.01.007  
 
